S100A8/A9 as a prognostic biomarker in lung transplantation

被引：2

作者：

Nakata, Kentaro ^{[1
,2
]}

Okazaki, Mikio ^{[1
,4
]}

Kawana, Shinichi ^{[1
]}

Kubo, Yujiro ^{[1
]}

Shimizu, Dai ^{[1
]}

Tanaka, Shin ^{[1
,3
]}

Hashimoto, Kohei ^{[1
,3
]}

Suzawa, Ken ^{[1
]}

Shien, Kazuhiko ^{[1
]}

Miyoshi, Kentaroh ^{[1
,3
]}

Yamamoto, Hiromasa ^{[1
]}

Sugimoto, Seiichiro ^{[1
,3
]}

Toyooka, Shinichi ^{[1
]}

机构：

[1] Okayama Univ, Dept Gen Thorac Surg & Breast & Endocrinol Surg, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, Okayama, Japan

[2] Duke Univ, Dept Surg, Div Cardiovasc & Thorac Surg, Sch Med, Durham, NC USA

[3] Okayama Univ Hosp, Organ Transplant Ctr, Kita Ku, Okayama, Japan

[4] Okayama Univ, Dept Gen Thorac Surg & Breast & Endocrinol Surg, Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Kita Ku, Okayama 7008558, Japan

来源：

CLINICAL TRANSPLANTATION | 2023年 / 37卷 / 09期

基金：

日本学术振兴会;

关键词：

chronic lung allograft dysfunction; damage-associated molecular patterns; long-term survival; lung transplantation; primary graft dysfunction; prognostic biomarker; A9; PRIMARY GRAFT DYSFUNCTION; ISCHEMIC TIME; EXPRESSION; PATTERNS;

D O I：

10.1111/ctr.15006

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

ObjectivesS100A8/A9 is a damage-associated molecule that augments systemic inflammation. However, its role in the acute phase after lung transplantation (LTx) remains elusive. This study aimed to determine S100A8/A9 levels after lung transplantation (LTx) and evaluate their impact on overall survival (OS) and chronic lung allograft dysfunction (CLAD)-free survival. MethodsSixty patients were enrolled in this study, and their plasma S100A8/A9 levels were measured on days 0, 1, 2, and 3 after LTx. The association of S100A8/A9 levels with OS and CLAD-free survival was assessed using univariate and multivariate Cox regression analyses. ResultsS100A8/A9 levels were elevated in a time-dependent manner until 3 days after LTx. Ischemic time was significantly longer in the high S100A8/9 group than in the low S100A8/A9 group (p = .017). Patients with high S100A8/A9 levels (> 2844 ng/mL) had worse prognosis (p = .031) and shorter CLAD-free survival (p = .045) in the Kaplan-Meier survival analysis than those with low levels. Furthermore, multivariate Cox regression analysis showed that high S100A8/A9 levels were a determinant of poor OS (hazard ratio [HR]: 3.7; 95% confidence interval [CI]: 1.2-12; p = .028) and poor CLAD-free survival (HR: 4.1; 95% CI: 1.1-15; p = .03). In patients with a low primary graft dysfunction grade (0-2), a high level of S100A8/A9 was also a poor prognostic factor. ConclusionsOur study provided novel insights into the role of S100A8/A9 as a prognostic biomarker and a potential therapeutic target for LTx.

引用

页数：8

共 35 条

[1] Extracellular HMGB1 as a therapeutic target in inflammatory diseases [J].